IL-12p40 is essential but not sufficient for Francisella tularensis LVS clearance in chronically infected mice

por Mittereder, Lara R., Swoboda, Jonathan, De Pascalis, Roberto, Elkins, Karen L.
Publicado 2023

The Dysbiosis Triggered by First-Line Tuberculosis Antibiotics Fails to Reduce Their Bioavailability

por Namasivayam, Sivaranjani, Zimmerman, Matthew, Oland, Sandra, Wang, Han, Mittereder, Lara R., Dartois, Véronique, Sher, Alan
Publicado 2023

Enhancement of CD4(+) T Cell Function as a Strategy for Improving Antibiotic Therapy Efficacy in Tuberculosis: Does It Work?

por Costa, Diego L., Amaral, Eduardo P., Namasivayam, Sivaranjani, Mittereder, Lara R., Andrade, Bruno B., Sher, Alan
Publicado 2021

Correlation between Disease Severity and the Intestinal Microbiome in Mycobacterium tuberculosis-Infected Rhesus Macaques

por Namasivayam, Sivaranjani, Kauffman, Keith D., McCulloch, John A., Yuan, Wuxing, Thovarai, Vishal, Mittereder, Lara R., Trinchieri, Giorgio, Barber, Daniel L., Sher, Alan
Publicado 2019

Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

por Namasivayam, Sivaranjani, Maiga, Mamoudou, Yuan, Wuxing, Thovarai, Vishal, Costa, Diego L., Mittereder, Lara R., Wipperman, Matthew F., Glickman, Michael S., Dzutsev, Amiran, Trinchieri, Giorgio, Sher, Alan
Publicado 2017

Heme oxygenase-1 inhibition promotes IFNγ and NOS2 mediated control of Mycobacterium tuberculosis infection

por Costa, Diego L, Amaral, Eduardo P, Namasivayam, Sivaranjani, Mittereder, Lara R, Fisher, Logan, Bonfim, Caio C, Sardinha-Silva, Aline, Thompson, Robert W, Hieny, Sara E, Andrade, Bruno B, Sher, Alan
Publicado 2020

Pharmacological Inhibition of Host Heme Oxygenase-1 Suppresses Mycobacterium tuberculosis Infection In Vivo by a Mechanism Dependent on T Lymphocytes

por Costa, Diego L., Namasivayam, Sivaranjani, Amaral, Eduardo P., Arora, Kriti, Chao, Alex, Mittereder, Lara R., Maiga, Mamoudou, Boshoff, Helena I., Barry, Clifton E., Goulding, Celia W., Andrade, Bruno B., Sher, Alan
Publicado 2016

Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer

por Bennett, Christina N, Tomlinson, Christine C, Michalowski, Aleksandra M, Chu, Isabel M, Luger, Dror, Mittereder, Lara R, Aprelikova, Olga, Shou, James, Piwinica-Worms, Helen, Caplen, Natasha J, Hollingshead, Melinda G, Green, Jeffrey E
Publicado 2012